Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial - The Lancet Haematology
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial -
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement | Leukemia
Newly Diagnosed: D + RD Treatment | DARZALEX® IV (daratumumab)
Maintenance Therapy with Revlimid for Multiple Myelom
No Survival Benefit With All-Oral Regimen for Relapsed/Refractory Myeloma | MedPage Today
Velcade, Revlimid, and Dexamethasone Combination Remains Standard-of-Care First-Line Therapy for Patients with Multiple Myeloma - Conquer: the journey informed
Daratumumab regimen safe, effective in newly diagnosed multiple myeloma
Treatment schema for newly diagnosed multiple myeloma and commonly used... | Download Scientific Diagram
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan | SpringerLink
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
Newly Diagnosed: D + VTD Treatment | DARZALEX® IV (daratumumab)
Tip Card: The VRd Regimen by International Myeloma Foundation - Issuu
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma - ScienceDirect
Relapsed: D + RD Treatment | DARZALEX® IV (daratumumab)
![PDF] A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c492928e3f0ff31a9045ef665d1d8113a4831731/3-Figure1-1.png "PDF] A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma | Semantic Scholar")
PDF] A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma | Semantic Scholar
British Journal of Haematology | Wiley Online Library
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma | Blood Cancer Journal
DRd Trial Design & Efficacy | REVLIMID® (lenalidomide)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
547-Lenalidomide and dexamethasone oral | eviQ
Relapsed: D + RD Treatment | DARZALEX® IV (daratumumab)
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
